At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGTX Cognition Therapeutics, Inc
Trading 10-15 14:25:02 EDT
0.7204
-0.0563
-7.25%
High0.7663Low0.7201Vol530.40K
Open0.7580D1 Closing0.7767Amplitude5.95%
Mkt Cap68.51MTradable Cap61.54MTotal Shares95.09M
T/O390.25KT/O Rate0.62%Tradable Shares85.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cognition Therapeutics: Patent Extension and Pivotal CNS Catalysts Support Buy Rating with Unchanged $3 Price Target
TIPRANKS  ·  10-14 23:35
Cognition Therapeutics: Patent Extension and Pivotal CNS Catalysts Support Buy Rating with Unchanged $3 Price Target
Cognition Therapeutics issued patent extending protection for zervimesine
TIPRANKS  ·  10-13 18:11
Cognition Therapeutics issued patent extending protection for zervimesine
Cognition Therapeutics Wins US Patent for New Crystalline Form of Zervimesine Through 2045
Reuters  ·  10-13 18:01
Cognition Therapeutics Wins US Patent for New Crystalline Form of Zervimesine Through 2045
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (Ct1812) Through 2045
THOMSON REUTERS  ·  10-13 18:00
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (Ct1812) Through 2045
Cognition Therapeutics - FDA Meeting Scheduled Next Week for Dlb Program; Manufacturing Planned Q1 2027
THOMSON REUTERS  ·  10-13 18:00
Cognition Therapeutics - FDA Meeting Scheduled Next Week for Dlb Program; Manufacturing Planned Q1 2027
Cognition Therapeutics - Patent Expires in 2045; May be Extended up to Five Years upon FDA Approval
THOMSON REUTERS  ·  10-13 18:00
Cognition Therapeutics - Patent Expires in 2045; May be Extended up to Five Years upon FDA Approval
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
GlobeNewswire  ·  10-13 18:00
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812
TIPRANKS  ·  09-29
Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (Ct1812) in DLB
Reuters  ·  09-29
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (Ct1812) in DLB
Cognition Therapeutics - Meeting to Align on Primary Endpoint for Zervimesine Phase 3 Dlb Study
THOMSON REUTERS  ·  09-29
Cognition Therapeutics - Meeting to Align on Primary Endpoint for Zervimesine Phase 3 Dlb Study
Cognition Therapeutics - Schedules Type C FDA Meeting for October 20, 2026
THOMSON REUTERS  ·  09-29
Cognition Therapeutics - Schedules Type C FDA Meeting for October 20, 2026
Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  09-22
Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright
Amazon - Cognition and AWS Sign Multi-Year Strategic Collaboration Agreement
THOMSON REUTERS  ·  09-15
Amazon - Cognition and AWS Sign Multi-Year Strategic Collaboration Agreement
Cognition Therapeutics CEO Lisa Ricciardi Presents at H.C. Wainwright Global Investment Conference
Reuters  ·  09-08
Cognition Therapeutics CEO Lisa Ricciardi Presents at H.C. Wainwright Global Investment Conference
Soligenix Q2 Net Loss Narrows as R&D Expenses Fall
Reuters  ·  08-07
Soligenix Q2 Net Loss Narrows as R&D Expenses Fall
Cognition Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-07
Cognition Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)
TIPRANKS  ·  08-07
Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate
Benzinga Earnings  ·  08-07
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
THOMSON REUTERS  ·  08-07
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
Cognition Therapeutics Q2 Income from Operations USD -7.738 Million
THOMSON REUTERS  ·  08-07
Cognition Therapeutics Q2 Income from Operations USD -7.738 Million

Introduction

Company Name.
Cognition Therapeutics, Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Issue price:
--